Generation of urothelial cancer organoids to investigate tumor biology in organoids and to perform drug sensitivity testing.

• Conditions: bladder cancer; Urothelial cancer; 10038364; 10004994

• Registration Number: NL-OMON52018
• Lead Sponsor: Erasmus MC, Universitair Medisch Centrum Rotterdam

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 15 April 2024

Recruitment & Eligibility

• Status: Pending
• Sex: Not specified
• Target Recruitment: 117

Inclusion Criteria

• Age >= 18 years at time of inclusion
• Written informed consent
• Able to read and understand the patient information
• Mentally and physically able to participate according to the treating
physician.

Exclusion Criteria

• Known HIV-infection or other serious infectious disease which can be
transferred by one of the biomaterials.

Study & Design

• Study Type: Observational invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>- If we can use the near-patient organoid model to predict response to treatment<br /><br>- If the organoid immune microenvironment changes in relation to drug treatment</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>Not applicable.</p><br>